Changes in Mifepristone Use at Pharmacies After Removal of the FDA In-Person Dispensing Requirement
Key Points
This study aims to evaluate how the removal of the FDA’s in-person dispensing requirement affects access to mifepristone.
Cross-sectional design
Assessment of retail and mail-order pharmacy access
Comparison before and after the FDA policy change
Increased availability of mifepristone at retail pharmacies
Growth in mail-order pharmacy access
Greater overall access to medication after policy modification
Abstract
This cross-sectional study examines access to mifepristone through retail and mail-order pharmacies following the US Food and Drug Administration’s (FDA) removal of its in-person dispensing requirement.
Like
Bookmark
Share
Like
Bookmark
Share
Changes in Mifepristone Use at Pharmacies After Removal of the FDA In-Person Dispensing Requirement | Synapse